NCCN VERSION 2 2015

142 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-67
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A
Cancer Journal for Clinicians 2014:n/a-n/a. Available at:
.
2. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013.
CA Cancer J Clin 2014;64:52-62. Available at:
.
3. Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: an overview of the
randomised trials. Lancet 2005;365:1687-1717. Available at:
.
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the
impact of eliminating socioeconomic and racial disparities on premature
cancer deaths. CA Cancer J Clin 2011;61:212-236. Available at:
.
5. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and
adjuvant therapy on mortality from breast cancer. N Engl J Med
2005;353:1784-1792. Available at:
.
6. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and
benefits of tamoxifen treatment for preventing breast cancer. J Natl
Cancer Inst 1999;91:1829-1846. Available at:
.
7. Dupont WD, Page DL. Risk factors for breast cancer in women with
proliferative breast disease. N Engl J Med 1985;312:146-151. Available
at:
8. Dupont WD, Page DL. Risk factors for breast cancer in women with
proliferative breast disease. N Engl J Med 1985;312:146-151. Available
at:
9. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging
Manual, 7th Edition. New York: Springer; 2010.
10. White J, Morrow M, Moughan J, et al. Compliance with breast-
conservation standards for patients with early-stage breast carcinoma.
Cancer 2003;97:893-904. Available at:
.
11. Wilkinson NW, Shahryarinejad A, Winston JS, et al. Concordance
with breast cancer pathology reporting practice guidelines. J Am Coll
Surg 2003;196:38-43. Available at:
.
12. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and
predictive factors in breast cancer by immunohistochemical analysis.
Mod Pathol 1998;11:155-168. Available at:
13. Rhodes A, Jasani B, Barnes DM, et al. Reliability of
immunohistochemical demonstration of oestrogen receptors in routine
practice: interlaboratory variance in the sensitivity of detection and
evaluation of scoring systems. J Clin Pathol 2000;53:125-130. Available
at:
14. Rudiger T, Hofler H, Kreipe HH, et al. Quality assurance in
immunohistochemistry: results of an interlaboratory trial involving 172
pathologists. Am J Surg Pathol 2002;26:873-882. Available at:
.
15. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report:
Estrogen receptor and progesterone receptor testing in breast cancer
by immunohistochemistry. J Natl Compr Canc Netw 2009;7 Suppl 6:S1-
S21; quiz S22-23. Available at:
.
16. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of
Clinical Oncology/College Of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and